Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer

M. S. Kopreski, F. A. Benko, C. Kwee, K. E. Leitzel, E. Eskander, A. Lipton, Christopher Gocke

Research output: Contribution to journalArticle

Abstract

Increased understanding of the molecular basis of colorectal cancer and recognition that extracellular DNA circulates in the plasma and serum of cancer patients enables new approaches to detection and monitoring. We used a polymerase chain reaction (PCR) assay to demonstrate mutant K-ras DNA in the plasma or serum of patients with colorectal cancer. Plasma or serum was fractionated from the blood of 31 patients with metastatic or unresected colorectal cancer and from 28 normal volunteers. DNA was extracted using either a sodium chloride or a gelatin precipitation method and then amplified in a two-stage PCR assay using selective restriction enzyme digestion to enrich for mutant K-ras DNA. Mutant K-ras DNA was detected in the plasma or serum of 12 (39%) patients, all confirmed by sequencing, but was not detected in any of the normal volunteers. K-ras mutations were detected in plasma or serum regardless of sex, primary tumour location, principal site of metastasis or proximity of chemotherapy and surgery to blood sampling. Tumour specimens available for 19 of the patients were additionally assayed for ras mutations and compared with blood specimens. Our results indicate mutant K-ras DNA is readily detectable by PCR in the plasma or serum of patients with advanced colorectal cancer. Thus, plasma- or serum-based nucleic acid amplification assays may provide a valuable method of monitoring and potentially detecting colorectal cancer.

Original languageEnglish (US)
Pages (from-to)1293-1299
Number of pages7
JournalBritish Journal of Cancer
Volume76
Issue number10
StatePublished - 1997
Externally publishedYes

Fingerprint

Colorectal Neoplasms
DNA
Serum
Polymerase Chain Reaction
Healthy Volunteers
Neoplasms
Mutation
Gelatin
Sodium Chloride
Nucleic Acids
Digestion
Neoplasm Metastasis
Drug Therapy
Enzymes

Keywords

  • Colorectal cancer
  • DNA
  • K-ras
  • Plasma
  • Polymerase chain reaction
  • Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kopreski, M. S., Benko, F. A., Kwee, C., Leitzel, K. E., Eskander, E., Lipton, A., & Gocke, C. (1997). Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. British Journal of Cancer, 76(10), 1293-1299.

Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. / Kopreski, M. S.; Benko, F. A.; Kwee, C.; Leitzel, K. E.; Eskander, E.; Lipton, A.; Gocke, Christopher.

In: British Journal of Cancer, Vol. 76, No. 10, 1997, p. 1293-1299.

Research output: Contribution to journalArticle

Kopreski, MS, Benko, FA, Kwee, C, Leitzel, KE, Eskander, E, Lipton, A & Gocke, C 1997, 'Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer', British Journal of Cancer, vol. 76, no. 10, pp. 1293-1299.
Kopreski MS, Benko FA, Kwee C, Leitzel KE, Eskander E, Lipton A et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. British Journal of Cancer. 1997;76(10):1293-1299.
Kopreski, M. S. ; Benko, F. A. ; Kwee, C. ; Leitzel, K. E. ; Eskander, E. ; Lipton, A. ; Gocke, Christopher. / Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. In: British Journal of Cancer. 1997 ; Vol. 76, No. 10. pp. 1293-1299.
@article{5fce6d58ecb9488f8ef0faad1d362906,
title = "Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer",
abstract = "Increased understanding of the molecular basis of colorectal cancer and recognition that extracellular DNA circulates in the plasma and serum of cancer patients enables new approaches to detection and monitoring. We used a polymerase chain reaction (PCR) assay to demonstrate mutant K-ras DNA in the plasma or serum of patients with colorectal cancer. Plasma or serum was fractionated from the blood of 31 patients with metastatic or unresected colorectal cancer and from 28 normal volunteers. DNA was extracted using either a sodium chloride or a gelatin precipitation method and then amplified in a two-stage PCR assay using selective restriction enzyme digestion to enrich for mutant K-ras DNA. Mutant K-ras DNA was detected in the plasma or serum of 12 (39{\%}) patients, all confirmed by sequencing, but was not detected in any of the normal volunteers. K-ras mutations were detected in plasma or serum regardless of sex, primary tumour location, principal site of metastasis or proximity of chemotherapy and surgery to blood sampling. Tumour specimens available for 19 of the patients were additionally assayed for ras mutations and compared with blood specimens. Our results indicate mutant K-ras DNA is readily detectable by PCR in the plasma or serum of patients with advanced colorectal cancer. Thus, plasma- or serum-based nucleic acid amplification assays may provide a valuable method of monitoring and potentially detecting colorectal cancer.",
keywords = "Colorectal cancer, DNA, K-ras, Plasma, Polymerase chain reaction, Serum",
author = "Kopreski, {M. S.} and Benko, {F. A.} and C. Kwee and Leitzel, {K. E.} and E. Eskander and A. Lipton and Christopher Gocke",
year = "1997",
language = "English (US)",
volume = "76",
pages = "1293--1299",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer

AU - Kopreski, M. S.

AU - Benko, F. A.

AU - Kwee, C.

AU - Leitzel, K. E.

AU - Eskander, E.

AU - Lipton, A.

AU - Gocke, Christopher

PY - 1997

Y1 - 1997

N2 - Increased understanding of the molecular basis of colorectal cancer and recognition that extracellular DNA circulates in the plasma and serum of cancer patients enables new approaches to detection and monitoring. We used a polymerase chain reaction (PCR) assay to demonstrate mutant K-ras DNA in the plasma or serum of patients with colorectal cancer. Plasma or serum was fractionated from the blood of 31 patients with metastatic or unresected colorectal cancer and from 28 normal volunteers. DNA was extracted using either a sodium chloride or a gelatin precipitation method and then amplified in a two-stage PCR assay using selective restriction enzyme digestion to enrich for mutant K-ras DNA. Mutant K-ras DNA was detected in the plasma or serum of 12 (39%) patients, all confirmed by sequencing, but was not detected in any of the normal volunteers. K-ras mutations were detected in plasma or serum regardless of sex, primary tumour location, principal site of metastasis or proximity of chemotherapy and surgery to blood sampling. Tumour specimens available for 19 of the patients were additionally assayed for ras mutations and compared with blood specimens. Our results indicate mutant K-ras DNA is readily detectable by PCR in the plasma or serum of patients with advanced colorectal cancer. Thus, plasma- or serum-based nucleic acid amplification assays may provide a valuable method of monitoring and potentially detecting colorectal cancer.

AB - Increased understanding of the molecular basis of colorectal cancer and recognition that extracellular DNA circulates in the plasma and serum of cancer patients enables new approaches to detection and monitoring. We used a polymerase chain reaction (PCR) assay to demonstrate mutant K-ras DNA in the plasma or serum of patients with colorectal cancer. Plasma or serum was fractionated from the blood of 31 patients with metastatic or unresected colorectal cancer and from 28 normal volunteers. DNA was extracted using either a sodium chloride or a gelatin precipitation method and then amplified in a two-stage PCR assay using selective restriction enzyme digestion to enrich for mutant K-ras DNA. Mutant K-ras DNA was detected in the plasma or serum of 12 (39%) patients, all confirmed by sequencing, but was not detected in any of the normal volunteers. K-ras mutations were detected in plasma or serum regardless of sex, primary tumour location, principal site of metastasis or proximity of chemotherapy and surgery to blood sampling. Tumour specimens available for 19 of the patients were additionally assayed for ras mutations and compared with blood specimens. Our results indicate mutant K-ras DNA is readily detectable by PCR in the plasma or serum of patients with advanced colorectal cancer. Thus, plasma- or serum-based nucleic acid amplification assays may provide a valuable method of monitoring and potentially detecting colorectal cancer.

KW - Colorectal cancer

KW - DNA

KW - K-ras

KW - Plasma

KW - Polymerase chain reaction

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=0030724379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030724379&partnerID=8YFLogxK

M3 - Article

C2 - 9374374

AN - SCOPUS:0030724379

VL - 76

SP - 1293

EP - 1299

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -